Last reply 4 months ago
NICE

FYI
The NICE approved sister of Lemtrada (alemtuzumab); has been withdrawn worldwide for treatment for R/R MS, I note from the British Medical Journal.

And it had been apparently throughly trialed before NICE accepted it.
You should read the bumfth on it!

…and clearly a fairy story, they now realise …

I’ve cut and pasted for you, if you are interested …

“Biogen and AbbVie have announced the voluntary worldwide withdrawal of marketing authorisations for daclizumab (Zinbryta) for the treatment of relapsing multiple sclerosis (MS) as a result of the “complex and evolving benefit/risk profile” of the drug.1 Following seven reported cases of inflammatory brain disorders (encephalitis and meningoencephalitis) associated with daclizumab, the European Medicines Agency (EMA) began an urgent review of the safety of the drug.2”

Just sayin….

Thoughts?

Oh n sending lots of love to you all, you all inspire and amaze ✨👍👏🌈💕✨

Add categories

Browse categories and add by clicking on them

You can remove current categories below by clicking the ‘x’.

Join Shift.ms to reply to this post.

Become part of the community so you can chat, compare and learn from other MSers.